InvestorsHub Logo
Followers 2
Posts 1798
Boards Moderated 0
Alias Born 01/05/2017

Re: runcaly post# 21072

Tuesday, 05/30/2017 8:39:51 AM

Tuesday, May 30, 2017 8:39:51 AM

Post# of 108192
The reason BMS is making that statement is because BMS Opdivo just failed a trial in lung cancer and MERK got a One up BMS....

So BMS Opdivo is fading market expectations and MERK keytruda is gaining market expectations....

“Combining immunotherapy agents is at the core of Bristol-Myers Squibb’s strategy, as it brings the opportunity to improve anti-tumor efficacy,”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News